Immunology and inflammation pipeline and market
Immunology and inflammation pipeline and market
AbbVie has completed its $10.9 billion acquisition of Apogee Therapeutics, adding zumilokibart — a long-acting interleukin-13 antibody positioned against Dupixent — to its immunology portfolio.
Eli Lilly agreed to acquire Merida Biosciences for up to $2.9 billion, adding a precision antibody-targeting platform to its immunology pipeline as the company’s 2026 acquisition total surpasses $31 billion.
You must be logged in to post a comment.